Iron Dextran Injection

1. Introduction

Neonatal animals are born with limited iron reserves, while their iron requirement increases markedly during periods of rapid growth. The iron supplied through maternal milk alone is insufficient to meet this demand; without timely supplementation, iron-deficiency anemia may develop, leading to growth retardation. At present, iron dextran injections available on the market vary widely in price and quality. In some cases, piglets aged 1–3 days or other young animals have experienced adverse reactions or even death following injection. Irontong addresses these issues through careful selection of the iron source, optimized chelation processes, and precise control of molecular weight and molecular weight distribution, thereby effectively overcoming the limitations of conventional iron supplements.

2. Key Technical Features

2.1 Optimal Molecular Weight and Molecular Weight Distribution (Figure 1)

The molecular weight and its distribution are critical indicators of the quality of iron dextran injections. An excessively low molecular weight may result in incomplete chelation, with free iron causing allergic reactions or even death in young animals. Conversely, an excessively high molecular weight leads to increased viscosity, poor absorption, and discoloration at the injection site. Clinical validation indicates that a molecular weight of approximately 6,000–6,500 Da and a distribution coefficient of 1.3–1.5 can effectively minimize adverse reactions while ensuring optimal absorption.

2.2 Stable Chelation and Formulation Process

High-quality iron sources are reacted with dextran of 5,000–7,500 Da under specific conditions to form a stable chelate, ensuring that both molecular weight and distribution coefficient remain within the optimal range. Free iron is removed by ultrafiltration to reduce allergic reactions, while free dextran is separated by ethanol precipitation. Pyrogens are eliminated through dialysis, resulting in an iron dextran injection with minimal adverse reactions, easy injectability, and good absorption (Irontong).

3. Clinical Applications

3.1 Indications

1. Iron deficiency in neonatal piglets, anemia caused by other trace element deficiencies in piglets, and anemia and growth retardation resulting from hemoprotozoan diseases.
2. Blood loss in livestock; pallor of the skin; erythrocyte reduction caused by eperythrozoonosis, characterized by depression, inappetence, isolation and recumbency, normal or slightly elevated body temperature, rough and dull hair coat, pica, emaciation, ataxia, eyelid or subcutaneous edema, malnutrition, and growth retardation.

3.2 Dosage and Administration

1. Prevention of iron-deficiency anemia in piglets: Administer 1 ml by deep intramuscular injection in the neck at 1–3 days of age.
2. Postpartum prevention of iron-deficiency anemia and anti-inflammatory support in sows: Inject 3–4 ml; may be used in combination with ceftiofur sodium for injection.
3. Anemia caused by hemoprotozoan diseases in cattle and sheep: Inject 5–10 ml for cattle and 3–5 ml for sheep, in combination with appropriate anti-hemoprotozoan therapy.

4. Precautions

1. This product has relatively high toxicity; intramuscular dosage must be strictly controlled.
2. Intramuscular injection may cause local pain; deep intramuscular injection is recommended.
3. Injection in pigs older than 4 weeks may result in discoloration of the gluteal muscles.
4. Protect from freezing; precipitation may occur after prolonged storage.
5. Iron salts may react with many chemical substances or drugs; therefore, this product should not be administered concurrently or mixed with other medications for oral use. In rare cases, individual piglets may exhibit muscle weakness and unsteady standing after iron injection; in severe cases, this may result in death.